TABLE 1

Patient Data, ROIs, and SUV_cors

Patient	Age (y)	Sex	Tumor status	Tumor histology	Ann Arbor	Chemotherapy	No. of ROIs	SUV_cor* at:
Patient	Age (y)	Sex	Tumor status	Tumor histology	Ann Arbor	Chemotherapy	No. of ROIs					Baseline	Day 1	Day 20	End
1	57	F	Primary	B-cell follicular mixed	III	R-CHOP	6	9.2 (7.2 ± 1.9)	0.5 (0.6 ± 0.6)	0.5 (0.5 ± 0.7)	0.0 (0.0 ± 0.0)
2	52	F	Primary	B-cell diffuse large	III	R-CHOP	4	7.7 (5.7 ± 1.5)	1.2 (1.0 ± 0.3)	0.0 (0.0 ± 0.0)	0.0 (0.0 ± 0.0)
3	81	F	Relapsed	B-cell follicular mixed	II	R-THP-COP	2	2.1 (1.7 ± 0.6)	0.5 (0.5 ± 0.1)	0.0 (0.0 ± 0.0)	0.0 (0.0 ± 0.0)
4	51	M	Primary	B-cell follicular mixed	III	R-CHOP	9	12.5 (6.7 ± 4.5)	6.8 (2.2 ± 2.3)	2.7 (1.0 ± 1.3)	0.0 (0.0 ± 0.0)
5	32	M	Primary	B-cell diffuse large	II	CHOP	9	27.4 (6.6 ± 7.8)	19.5 (3.6 ± 6.0)	1.5 (0.6 ± 0.4)	0.0 (1.2 ± 0.8)
6	66	F	Primary	B-cell follicular mixed	III	R-CHOP	3	7.2 (6.7 ± 0.7)	3.5 (3.1 ± 0.8)	0.0 (0.0 ± 0.0)	0.0 (0.0 ± 0.0)
7	68	M	Relapsed	B-cell follicular	II	R-THP-COP	1	4.4	2.4	0.0	2.1
8	81	F	Relapsed	T-cell	II	THP-COP	1	7.6	4.3	1.2	1.2
9	77	F	Relapsed	B-cell follicular mixed	III	R-VeMP	9	5.7 (3.4 ± 1.4)	4.5 (2.2 ± 1.5)	2.5 (1.3 ± 0.6)	0.0 (0.2 ± 0.2)
10	66	F	Primary	B-cell diffuse large	IV	R-CHO	6	23.7 (11.7 ± 8.4)	13.5 (6.6 ± 5.2)	0.3 (0.1 ± 0.1)	1.1 (0.2 ± 0.4)
11	58	M	Relapsed	B-cell follicular	II	R-CHOP	2	4.4 (3.5 ± 1.3)	2.4 (2.5 ± 0.1)	0.0 (0.0 ± 0.0)	0.0 (0.0 ± 0.0)
12	76	M	Primary	B-cell diffuse mixed	II	R-CHOP	4	16.2 (8.5 ± 5.0)	10.0 (6.7 ± 2.5)	0.0 (0.0 ± 0.0)	0.0 (0.0 ± 0.0)
Mean ± SD								10.7 ± 7.9	5.8 ± 5.8	0.7 ± 1.0	0.4 ± 0.7

↵* Data are representative index for ROI with highest SUV_cor at baseline ¹⁸F-FDG PET for each patient (mean ± SD for all ROIs).
R = rituximab; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisolone; THP-COP = pirarubicin, cyclophosphamide, vincristine, and prednisolone; VeMP = mitoxantrone, etoposide, and prednisolone.